MedAdvisor Future Growth

Future criteria checks 4/6

MedAdvisor is forecast to grow earnings and revenue by 69.1% and 13.4% per annum respectively. EPS is expected to grow by 69.2% per annum. Return on equity is forecast to be 18.1% in 3 years.

Key information

69.1%

Earnings growth rate

69.2%

EPS growth rate

Healthcare Services earnings growth	20.8%
Revenue growth rate	13.4%
Future return on equity	18.1%
Analyst coverage	Low
Last updated	01 Nov 2024

Recent future growth updates

Recent updates

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Nov 09

Is MedAdvisor (ASX:MDR) A Risky Investment?

Oct 11

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Mar 08

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

Feb 10

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

Jan 18

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

Dec 22

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

Dec 18

Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation

Nov 22

Earnings and Revenue Growth Forecasts

ASX:MDR - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2027	184	13	16	21	2
6/30/2026	162	9	14	16	3
6/30/2025	142	2	5	9	3
6/30/2024	122	1	3	5	N/A
3/31/2024	116	-4	-2	0	N/A
12/31/2023	109	-9	-7	-6	N/A
9/30/2023	104	-10	-4	-4	N/A
6/30/2023	98	-11	-2	-1	N/A
3/31/2023	96	-8	7	7	N/A
12/31/2022	93	-5	16	16	N/A
9/30/2022	80	-11	8	8	N/A
6/30/2022	68	-17	-1	0	N/A
3/31/2022	66	-16	-6	-5	N/A
12/31/2021	64	-14	-11	-11	N/A
9/30/2021	52	-14	-12	-12	N/A
6/30/2021	39	-14	-13	-13	N/A
3/31/2021	28	-13	-10	-9	N/A
12/31/2020	18	-12	-6	-6	N/A
9/30/2020	14	-11	-8	-7	N/A
6/30/2020	10	-10	-9	-9	N/A
3/31/2020	9	-9	-9	-8	N/A
12/31/2019	9	-9	-8	-8	N/A
9/30/2019	9	-8	-8	-7	N/A
6/30/2019	8	-8	-7	-7	N/A
3/31/2019	8	-7	-6	-6	N/A
12/31/2018	7	-7	-6	-5	N/A
9/30/2018	7	-6	-5	-4	N/A
6/30/2018	7	-4	-4	-3	N/A
3/31/2018	6	-4	N/A	-3	N/A
12/31/2017	6	-4	N/A	-3	N/A
9/30/2017	5	-4	N/A	-3	N/A
6/30/2017	4	-3	N/A	-2	N/A
3/31/2017	3	-4	N/A	-3	N/A
12/31/2016	2	-4	N/A	-3	N/A
9/30/2016	2	-4	N/A	-3	N/A
6/30/2016	1	-3	N/A	-3	N/A
3/31/2016	1	-2	N/A	-2	N/A
12/31/2015	2	-1	N/A	-1	N/A
9/30/2015	2	-1	N/A	-1	N/A
6/30/2015	2	-1	N/A	0	N/A
6/30/2014	1	-1	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDR's forecast earnings growth (69.1% per year) is above the savings rate (2.6%).

Earnings vs Market: MDR's earnings (69.1% per year) are forecast to grow faster than the Australian market (12.5% per year).

High Growth Earnings: MDR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MDR's revenue (13.4% per year) is forecast to grow faster than the Australian market (5.7% per year).

High Growth Revenue: MDR's revenue (13.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MDR's Return on Equity is forecast to be low in 3 years time (18.1%).

MedAdvisor Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Forecast breakeven date pushed back to 2025

Price target increased by 13% to AU$0.51

Consensus EPS estimates upgraded to AU$0.0033 loss

Forecast breakeven date moved forward to 2025

Consensus EPS estimates fall by 11%, revenue upgraded

Forecast breakeven date pushed back to 2026

Recent updates

New minor risk - Share price stability

New minor risk - Market cap size

Lacklustre Performance Is Driving MedAdvisor Limited's (ASX:MDR) Low P/S

MedAdvisor Limited Announces the Resignation of Anthony Tassone as Non-Executive Director

MedAdvisor Limited, Annual General Meeting, Nov 14, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

MedAdvisor Limited Announces Board Resignations

Forecast breakeven date pushed back to 2025

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Price target increased by 13% to AU$0.51

Consensus EPS estimates upgraded to AU$0.0033 loss

Forecast breakeven date moved forward to 2025

Consensus EPS estimates fall by 11%, revenue upgraded

Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Forecast breakeven date pushed back to 2026

New minor risk - Profitability

Now 24% overvalued after recent price rise

Consensus estimates of losses per share improve by 33%

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Non-Executive Director recently bought AU$1.2m worth of stock

MedAdvisor Limited, Annual General Meeting, Nov 28, 2023

Consensus estimates of losses per share improve by 32%

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 50%

MedAdvisor Limited Announces Board Changes

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Consensus EPS estimates fall by 80%, revenue upgraded

First half 2023 earnings released: EPS: AU$0.009 (vs AU$0.02 loss in 1H 2022)

Price target increased to AU$0.40

MedAdvisor Limited Provides Revenue Guidance for the First Half of the Fiscal Year 2023

MedAdvisor Limited Appoints Kevin Hutchinson as Director

Less than half of directors are independent

MedAdvisor Limited to Report Q1, 2023 Results on Oct 28, 2022

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited, Annual General Meeting, Nov 30, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

MedAdvisor Limited (ASX:MDR) entered a binding agreement to acquire GuildLink Pty Ltd from Guild Group Holdings Limited for AUD 8 million.

MedAdvisor Limited Announces Executive Changes

MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

MedAdvisor Limited Announces Change of Managing Director

Price target decreased to AU$0.40

No longer forecast to breakeven

Less than half of directors are independent

MedAdvisor Limited Announces Retirement of Robert Read as CEO

Consensus forecasts updated

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited to Report First Half, 2022 Results on Feb 25, 2022

MedAdvisor Limited Appoints Raeann Grossman to the Board as A Non-Executive Director

Independent Non-Executive Director Peter Bennetto has left the company

Non-Executive Director recently sold AU$2.5m worth of stock

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Is MedAdvisor (ASX:MDR) A Risky Investment?

Less than half of directors are independent

Full year 2021 earnings released

Non-Executive Director has left the company

MedAdvisor Limited announced that it has received AUD 5.25 million in funding

New 90-day low: AU$0.34

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

First half 2021 earnings released: AU$0.029 loss per share (vs AU$0.024 loss in 1H 2020)

MedAdvisor Limited to Report First Half, 2021 Results on Feb 25, 2021

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

New 90-day low: AU$0.34

Non-Executive Chairman of the Board recently bought AU$70k worth of stock

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

MedAdvisor Limited Signs an Additional One-Year Deal with A Major Global Pharmaceutical Company

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

New 90-day low: AU$0.36